Business
Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer
Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet medical need, today announced that it will host a virtual key opinion leader event focused on the evolving clinical and translational data supporting the development of (Z)-endoxifen, the Company's investigational selective estrogen receptor modulator/degrader, or SERM/D, as a potential next-generation endocri
About this update from Atossa Therapeutics, Inc.
[{"type":"text","content":"Event to feature Dr. Laura Esserman, internationally recognized surgical oncologist, breast cancer expert, and founder and principal investigator of the I-SPY Trials","length":165,"tagName":"p","attribs":{}},{"type":"text","content":"SEATTLE, May 14, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet medical need, today announced that it will host a virtual key opinion leader event focused on the evolving clinical and translational data supporting the development of (Z)-endoxifen, the Company's investigational selective estrogen receptor modulator/degrader, or SERM/D, as a potential next-generation endocrine therapy backbone across multiple estrogen receptor ("ER") -positive breast cancer settings.","length":666,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":127,"url":"https://media.zenfs.com/en/prnewswire.com/7d966dba69eaa17e1ae9804ff8449505"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LoNRij6WKpJ4_Q18om3GTg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIyNA--/https://media.zenfs.com/en/prnewswire.com/7d966dba69eaa17e1ae9804ff8449505","width":400,"height":127},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/colXtW1wv8TmxLifZC0D8w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTIwMw--/https://media.zenfs.com/en/prnewswire.com/7d966dba69eaa17e1ae9804ff8449505","width":400,"height":127}},"href":"https://mma.prnewswire.com/media/2685652/Atossa_Therapeutics_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The event will feature internationally recognized surgical oncologist and breast cancer expert Dr. Laura Esserman. Dr. Esserman serves as Director of the University of California San Francisco Breast Care Center and is the founder and principal investigator of the I-SPY Trials, an innovative platform designed to accelerate the development of personalized breast cancer therapies.","length":381,"tagName":"p"},{"type":"text","content":""Dr. Esserman has been at the forefront of innovation in breast cancer clinical research, adaptive trial design, and precision oncology for decades," said Dr. Stev...